- Oxford Biodynamics
- 13 August 2025 13:43:59
Source: Sharecast
The AIM-traded firm said that under the agreement, Google Cloud would provide computing resources to help the biotechnology company scale its proprietary EpiSwitch knowledge base and analytical tools, enabling high-throughput, AI-powered 3D genomic analysis in a secure and globally accessible environment.
Oxford said the partnership marked a significant step in its digital transformation, and would enhance its ability to serve pharmaceutical and biotech partners.
“Working with Google Cloud allows OBD to rapidly scale its analytical capabilities, bringing it closer to delivering precision 3D genomics insights in real time,” said executive chairman Iain Ross.
“Since joining the company, I have been convinced of the value of our 3D Genomics knowledgebase and the formation of this collaboration with Google Cloud only serves to validate this view.”
The company said the initiative would support containerised deployment, integration with Google Cloud’s AI and machine learning tools, and the creation of secure, scalable data processing pipelines that meet healthcare compliance standards.
Oxford BioDynamics said that would make its EpiSwitch platform more accessible to pharma and biotech companies and create new commercial opportunities.
At 1312 BST, shares in Oxford BioDynamics were up 11.97% at 0.42p.
Reporting by Josh White for Sharecast.com.